These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 30595364)

  • 1. Efficacy of Melatonin on Serum Pro-inflammatory Cytokines and Oxidative Stress Markers in Relapsing Remitting Multiple Sclerosis.
    Sánchez-López AL; Ortiz GG; Pacheco-Moises FP; Mireles-Ramírez MA; Bitzer-Quintero OK; Delgado-Lara DLC; Ramírez-Jirano LJ; Velázquez-Brizuela IE
    Arch Med Res; 2018 Aug; 49(6):391-398. PubMed ID: 30595364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.
    Ramirez-Ramirez V; Macias-Islas MA; Ortiz GG; Pacheco-Moises F; Torres-Sanchez ED; Sorto-Gomez TE; Cruz-Ramos JA; Orozco-Aviña G; Celis de la Rosa AJ
    Oxid Med Cell Longev; 2013; 2013():709493. PubMed ID: 23861993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of melatonin supplementation on plasma lipid hydroperoxides, homocysteine concentration and chronic fatigue syndrome in multiple sclerosis patients treated with interferons-beta and mitoxantrone.
    Adamczyk-Sowa M; Sowa P; Adamczyk J; Niedziela N; Misiolek H; Owczarek M; Zwirska-Korczala K
    J Physiol Pharmacol; 2016 Apr; 67(2):235-42. PubMed ID: 27226183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
    D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L
    Front Immunol; 2018; 9():1240. PubMed ID: 29915590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitting multiple sclerosis: relationship to oxidative stress.
    Bahamonde C; Conde C; Agüera E; Lillo R; Luque E; Gascón F; Feijóo M; Cruz AH; Sánchez-López F; Túnez I
    Eur J Pharmacol; 2014 May; 730():26-30. PubMed ID: 24582759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
    Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
    Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial.
    Sanoobar M; Eghtesadi S; Azimi A; Khalili M; Khodadadi B; Jazayeri S; Gohari MR; Aryaeian N
    Nutr Neurosci; 2015 May; 18(4):169-76. PubMed ID: 24621064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study.
    Stępień A; Chalimoniuk M; Lubina-Dąbrowska N; Chrapusta SJ; Galbo H; Langfort J
    Neuroimmunomodulation; 2013; 20(4):213-22. PubMed ID: 23711618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial.
    Zandi-Esfahan S; Fazeli M; Shaygannejad V; Hasheminia J; Badihian S; Aghayerashti M; Maghzi H
    Clin Neurol Neurosurg; 2017 Dec; 163():173-178. PubMed ID: 29126030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative Modification of Blood Serum Proteins in Multiple Sclerosis after Interferon Beta and Melatonin Treatment.
    Adamczyk-Sowa M; Galiniak S; Żyracka E; Grzesik M; Naparło K; Sowa P; Bartosz G; Sadowska-Bartosz I
    Oxid Med Cell Longev; 2017; 2017():7905148. PubMed ID: 29181127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis.
    Abo Taleb HA; Alghamdi BS
    J Mol Neurosci; 2020 Mar; 70(3):386-402. PubMed ID: 31713152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melatonin is able to prevent the liver of old castrated female rats from oxidative and pro-inflammatory damage.
    Kireev RA; Tresguerres AC; Garcia C; Ariznavarreta C; Vara E; Tresguerres JA
    J Pineal Res; 2008 Nov; 45(4):394-402. PubMed ID: 18573161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Control Trial Study to Determine the Effect of Melatonin on Serum Levels of IL-1β and TNF-α in Patients with Multiple Sclerosis.
    Yosefifard M; Vaezi G; Malekirad AA; Faraji F; Hojati V
    Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):649-654. PubMed ID: 32245308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of retinyl-palmitate on the level of pro and anti-inflammatory cytokines in multiple sclerosis patients: A randomized double blind clinical trial.
    Bitarafan S; Mohammadpour Z; Jafarirad S; Harirchian MH; Yekaninejad MS; Saboor-Yaraghi AA
    Clin Neurol Neurosurg; 2019 Feb; 177():101-105. PubMed ID: 30640138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.
    Orefice NS; Alhouayek M; Carotenuto A; Montella S; Barbato F; Comelli A; Calignano A; Muccioli GG; Orefice G
    Neurotherapeutics; 2016 Apr; 13(2):428-38. PubMed ID: 26857391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study.
    Landi D; Albanese M; Buttari F; Monteleone F; Boffa L; Rossi S; Motta C; Puma E; Centonze D
    PLoS One; 2017; 12(7):e0165415. PubMed ID: 28686675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.
    Gonsette RE; Sindic C; D'hooghe MB; De Deyn PP; Medaer R; Michotte A; Seeldrayers P; Guillaume D;
    Mult Scler; 2010 Apr; 16(4):455-62. PubMed ID: 20200198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.